The recurrence factors of triple negative breast cancer are mainly determined by the number of stages of the tumor and whether the adjuvant therapy performed is sufficient. At present, most triple negative breast cancers undergo preoperative chemotherapy and immunotherapy, and then complete remission (pCR) is determined based on the pathological report after surgery. If the effect is ideal, only one year of immunotherapy is needed, otherwise additional chemotherapy drugs need to be added to further reduce recurrence. In addition, many triple negative breast cancers are hereditary. Once confirmed to be hereditary, there is a targeted drug (PARPi) that can be taken to further reduce recurrence. Whether electrotherapy can prevent recurrence depends on the current situation of recurrence. If it is a local recurrence and the breast or chest has never received electrotherapy, surgery can be performed first before electrotherapy. If one has previously undergone electrotherapy, the likelihood of being suitable for further electrotherapy will be reduced, and the complications of further electrotherapy will also be significantly increased, so it will only be suitable for a very small number of patients. If tumor recurrence is already a diffuse condition, treatment aims to control the tumor. In some cases, local electrotherapy can prolong the time for the tumor to be controlled, but cannot completely prevent recurrence.